Tag: non-small cell lung cancer

1. Atezolizumab showed a benefit for disease-free survival in patients with stage II-IIIA NSCLC compared to best supportive treatment. 2. ...

1. Hypofractionated image-guided radiotherapy was not superior to conventionally fractionated radiotherapy monotherapy for patients with stage II/III non-small cell lung ...

1. Median overall survival and progression-free survival were significantly improved with cemiplimab monotherapy compared to chemotherapy. 2. Patients treated with ...

1. Osimertinib demonstrated a significantly longer duration of progression-free survival compared to standard of care epidermal growth factor receptor (EGFR)-tyrosine ...

1. Progression free survival and overall survival was significantly increased in patients who received pembrolizumab vs. patients who received platinum-based ...

1. Patients with advanced EGFR-associated non-small-cell lung cancer treated with dacomitinib had increased progression-free survival as compared to those without ...

1. Brachytherapy following sublobar resection (BSR) had no significant association with local NSCLC recurrence compared to sublobar resection (SR) alone. ...

Image: PD  1. In this meta-analysis, progression-free survival was longer with conventional chemotherapy compared to epidermal growth factor receptor inhibitor ...

Image: PD  1. There was a 58% response rate to ceritinib among non-small-cell lung cancer (NSCLC) patients.  2. Median progression-free ...

Image: PD 1. Pleural effusions were associated with worse survival in non-small-cell lung cancer (NSCLC), particularly when they arose in ...